GSK outlines rare disease strategy
This article was originally published in Scrip
Executive Summary
Having announced back in February that it was establishing a specific business unit to build a rare diseases franchise, GlaxoSmithKline is beginning to reveal what its focus and approach will be. Dr Shelagh Wilson, vice-president of business development, GSK Rare Diseases, spoke exclusively to Scrip following her presentation at BioPartnering Europe in London this week.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.